PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRegadenoson
Lexiscan, Rapiscan(regadenoson)
Lexiscan, Rapiscan, Regadenoson (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A3, adenosine receptor A1, and adenosine receptor A2b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
diagnosisD003933
Trade Name
FDA
EMA
Lexiscan, Regadenoson
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Regadenoson
Tradename
Company
Number
Date
Products
LEXISCANAstellas PharmaN-022161 RX2008-04-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lexiscanNew Drug Application2018-12-21
lexiscan(r) (regadenoson)New Drug Application2024-01-28
regadenosonANDA2025-04-03
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Regadenoson, Lexiscan, Astellas
RE473012027-02-02DP
81061832027-02-02DP
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01E: Other cardiac preparations in atc
— C01EB: Other plain cardiac preparations in atc
— C01EB21: Regadenoson
HCPCS
Code
Description
J2785
Injection, regadenoson, 0.1 mg
Clinical
Clinical Trials
95 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.1112—25
Myocardial ischemiaD017202EFO_1001375I20-I25112—14
Coronary diseaseD003327————2—13
Myocardial perfusion imagingD055414————1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRegadenoson
INNregadenoson
Description
Regadenoson is a purine nucleoside.
Classification
Small molecule
Drug classadenosine A receptor agonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O
Identifiers
PDB—
CAS-ID313348-27-5
RxCUI1546015
ChEMBL IDCHEMBL3989695
ChEBI ID—
PubChem CID219024
DrugBankDB06213
UNII ID7AXV542LZ4 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ADORA1
ADORA1
Organism
Homo sapiens
Gene name
ADORA1
Gene synonyms
NCBI Gene ID
134
Protein name
adenosine receptor A1
Protein synonyms
Uniprot ID
Q8TAM8
Mouse ortholog
Adora1 (11539)
adenosine receptor A1 (Q9WUF9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,781 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,935 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use